Alcohol and drug use is a common behavior among adolescents in the United States and other developed countries. A significant number of adolescents manifest problems with their substance use and may meet diagnostic criteria for a substance use disorder (SUD). The treatment of adolescent SUDs has begun to reflect the multifaceted nature of antecedents that lead to SUDs. These multiple problems need to be targeted for effective treatment. An empirical literature of treatment research for adolescents is emerging and provides clinicians with models and guidance for intervention with this often-difficult population.
DEFINITIONS
In this parameter, the term
adolescents refers to older children and adolescents.
Parent refers to a parent or legal guardian. The terminology in this practice parameter is consistent with that of the
Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (
DSM-IV-TR) (
American Psychiatric Association, 2001). The term
substance use disorders encompasses both substance abuse and substance dependence under the
DSM-IV-TR category of substance-related disorders. SUDs are defined for alcohol, amphetamine (or amphetamine-like), caffeine, cannabis, cocaine, hallucinogens, inhalants, nicotine, opioids, phencyclidine (or phencyclidine-like), and sedative, hypnotic, or anxiolytic agents.
Although the
DSM-IV-TR diagnoses of substance abuse and substance dependence assist clinicians in identifying adolescents with pathological patterns of substance use, the
DSM-IV-TR criteria, developed for adults, have not been established as applicable to adolescents (
Martin and Winters, 1998). While
DSM-IV-TR remains the guide for determining substance use-related pathology in adolescents, it is important to recognize the frequent differences between the most common manifestations of the diagnoses of substance abuse and dependence in adolescents versus adults. While substance use is a necessary prelude to abuse or dependence and early onset of regular use further increases the risk of SUDs, substance use per se is not sufficient for a diagnosis of abuse or dependence.
The diagnosis of substance abuse requires evidence of a maladaptive pattern of substance use with clinically significant levels of impairment or distress. Impairment means an inability to meet major role obligations leading to reduced functioning in one or more major areas of life, risk-taking behavior, an increase in the likelihood of legal problems due to possession, and exposure to hazardous situations. Substance dependence requires a substantial degree of involvement with a substance as evidenced by the adolescent's meeting at least three criteria from a group of seven criteria such as withdrawal, tolerance, and loss of control over use.
CLINICAL PRESENTATION
Despite similarities to adults in physical size and abilities, most adolescents have not obtained mature levels of cognitive, emotional, social, or physical growth. They are challenged by the developmental tasks of forming a separate identity and preparing for appropriate societal and individual roles including job, marriage, and family. Within a developmental context, adolescents experiment with a wide range of attitudes and behaviors including the use of psychoactive substances. Most adolescents experiment with using substances such as alcohol and cigarettes, and a portion of them later advance to the use of marijuana; a smaller portion proceed to the use of other drugs (
Kandel, 2002). The early onset of substance use and a more rapid progression through the stages of substance use are among the risk factors for the development of SUDs (
Robins and McEvoy, 1990).
Youths who present with substance use and frequent intoxication often manifest significant levels of acute change in mood, cognition, and behavior (Bukstein and Tarter, in press). Behavioral changes may include disinhibition, lethargy, hyperactivity or agitation, somnolence, and hypervigilance. Changes in cognition may include impaired concentration, changes in attention span, and perceptual and overt disturbances in thinking such as delusions. Mood changes can range from depression to euphoria. The manifestations of substance use and intoxication vary with the type of substance(s) used, the amount used during a given time period, the setting and context of use, and a host of characteristics of the individual such as experience with the substance, expectations of drug effect, and the presence or absence of other psychopathology.
A hallmark of SUDs in adolescents is impairment in psychosocial and academic functioning (
Martin and Winters, 1998). Impairment can include family conflict or dysfunction, interpersonal conflict, and academic failure. Associated characteristics include deviant and risk-taking behavior and comorbid psychiatric disorders such as conduct disorder, attention-deficit/hyperactivity disorder (ADHD), and mood, anxiety, and learning disorders (
Bukstein et al., 1989;
King et al., 2000;
Lewinsohn et al., 1993). Almost all psychoactive substances, including those available to adults such as alcohol and nicotine, are illegal for adolescents to obtain, possess, and use. Some of the negative consequences of substance use for adolescents follow from the illegal nature of these substances rather than from their actual use.
The course of SUDs in adolescents is variable (
Jaffe and Simkin, 2002;
Jaffe and Solhkhah, 2004). Adolescents with abuse often decrease or discontinue use in late adolescence or early adulthood, while those with dependence and more risk factors are more likely to continue to meet criteria for one or more SUDs.
TREATMENT
Recommendation 5. Adolescents with SUDs should receive specific treatment for their substance use [MS]
Reviews of the literature on adolescent treatment outcome have concluded that treatment is better than no treatment (
Deas and Thomas, 2001;
Williams and Chang, 2000). In the year after treatment, patients reported decreased heavy drinking, marijuana and other illicit drug use, and criminal involvement as well as improved psychological adjustment and school performance (
Grella et al., 2001;
Hser et al., 2001). Longer duration of treatment is associated with several favorable outcomes. Pretreatment factors associated with poorer outcomes (usually substance use and relapse to use) are nonwhite race, increased seriousness of substance use, criminality, and lower educational status. The intreatment factors predictive of outcome are time in treatment, involvement of family, use of practical problem solving, and provision of comprehensive services such as housing, academic assistance, and recreation. Posttreatment variables that are thought to be the most important determinants of outcome include association with nonusing peers and involvement in leisure time activities, work, and school. Variables reported to be most consistently related to successful outcome are treatment completion, low pretreatment use, and peer and parent social support and nonuse of substances.
In terms of empirical support for specific treatment modalities, family therapy approaches have the most supporting evidence (
Stanton and Shadish, 1997;
Williams and Chang, 2000), although individual approaches such as cognitive-behavioral therapy (CBT), both alone and with motivational enhancement, have shown to be efficacious (
Azrin et al., 2001 [rct];
Dennis et al., 2004 [rct];
Kaminer et al., 1998b,
1999 [rct];
Waldron et al., 2001 [rct]). Community reinforcement approaches using contingency contracting and vouchers also appear to be promising (
Azrin et al., 1994 [ct];
Corby et al., 2000 [ct];
Godley et al., 2002 [rct];
Kaminer, 2000). Selfsupport groups can be encouraged as adjuncts to these treatment modalities.
The primary goal of the treatment of adolescents with SUDs is achieving and maintaining abstinence from substance use. While abstinence should remain the explicit, long-term goal of treatment, a realistic view recognizes both the chronicity of SUDs in some populations of adolescents and the self-limited nature of substance use and substance use-related problems in others. Given these considerations, harm reduction may be an interim, implicit goal of treatment. Included in the concept of harm reduction is a reduction in the use and adverse effects of substances, a reduction in the severity and frequency of relapses, and improvement in one or more domains of the adolescent's functioning (e.g., academic performance or family functioning). While adolescents may not be initially motivated to stop substance use, the attainment of skills to deal with substance use may provide the adolescent with greater self-efficacy to not only reduce use but also ultimately move toward the goal of abstinence. Although harm reduction may be an interim goal of treatment, “controlled use” of any nonprescribed substance of abuse should never be an explicit goal in the treatment of adolescents. Control of substance use should not be the only goal of treatment. A broad concept of rehabilitation involves targeting associated problems and domains of functioning for treatment. Integrated interventions that concurrently deal with coexisting psychiatric and behavioral problems, family functioning, peer and interpersonal relationships, and academic/vocational functioning not only will produce general improvements in psychosocial functioning but most likely will yield improved outcomes in the primary treatment goal of achieving and maintaining abstinence.
Ongoing assessment of outcomes is important. The critical variables regarding current substance use are the use of specific substances during and after treatment with reference to the number of days of use per month, average amount per occasion, and maximum amount per occasion. Assessment of outcomes may also include determining the youth's compliance with treatment and involvement in 12-step programs.
Based on the combination of empirical research and current clinical consensus, the clinician dealing with adolescents with SUDs should develop a treatment plan that uses modalities that target (1) motivation and engagement; (2) family involvement to improve supervision, monitoring, and communication between parents and adolescent; (3) improved problem solving, social skills, and relapse prevention; (4) comorbid psychiatric disorders through psychosocial and/or medication treatments; (5) social ecology in terms of increasing prosocial behaviors, peer relationships, and academic functioning; and (6) adequate duration of treatment and follow-up care.
Recommendation 6. Adolescents with SUDs should be treated in the least restrictive setting that is safe and effective [MS]
Treatment of adolescents with SUDs can take place at one of several levels of care, reflecting intensity of treatment and restriction of movement (
American Academy of Child and Adolescent Psychiatry, 2001). Factors affecting the choice of treatment setting include the following: (1) the need to provide a safe environment and the ability of the adolescent to care for him- or herself; (2) motivation and willingness of the adolescent and his or her family to cooperate with treatment; (3) the adolescent's need for structure and limit-setting that cannot be provided in a less restrictive environment; (4) the existence of additional medical or psychiatric conditions; (5) the availability of specific types of treatment settings for adolescents; (6) the adolescent's and his or her family's preferences for a particular setting; and (7) treatment failure in a less restrictive setting or level of care. Although residential programs, including therapeutic communities (
Jainchill et al., 2000), have a place in the range of setting options, community intervention settings, if feasible, may offer optimal generalization of treatment gains. Even in the community, alternative sites such as home and school are being increasingly used (
Brown, 2001;
Wagner and Waldron, 2001).
Recommendation 7. Family therapy or significant family/parental involvement in treatment should be a component of treatment of SUDs [MS]
Family interventions are critical to the success of any treatment approach for adolescents with SUDs (
Stanton and Shadish, 1997;
Waldron, 1997) because a number of family-related factors, such as parental substance use or abuse, poor parent-child relationships, low perceived parental support, poor communication, and poor parent supervision and management of the adolescent's behavior, have been identified as risk factors for the development of substance abuse among adolescents. Three domains of predictors that have figured prominently in longitudinal studies of the etiology of adolescent substance use and SUDs are particularly relevant: characteristics of the parent-child relationship; parental effectiveness; and parental SUDs. Conflict between parents and adolescents, insufficient parental monitoring, inconsistent or otherwise ineffective discipline, child abuse/neglect, and parental alcoholism or other substance abuse have all been found to be robust correlates and predictors of adolescent substance use and SUDs (
Hawkins et al., 1992).
Although there are many approaches to family intervention for substance abuse treatment, they have common goals: providing psychoeducation about SUDs, which decreases familial resistance to treatment and increases motivation and engagement; assisting parents and family to initiate and maintain efforts to get the adolescent into appropriate treatment and achieve abstinence; assisting parents and family to establish or reestablish structure with consistent limit-setting and careful monitoring of the adolescent's activities and behavior; improving communication among family members; and getting other family members into treatment and/or support programs.
Family therapy is the most studied modality in the treatment of adolescents with SUDs. Based on the limited number of comparative studies, outpatient family therapy appears to be superior to other forms of outpatient treatment (
Deas and Thomas, 2001;
Waldron, 1997;
Williams and Chang, 2000). Among the forms of family therapy having support based on controlled studies are functional family therapy (
Alexander et al., 1990 [rct];
Friedman, 1989 [rct]), brief strategic family therapy (
Szapocznik et al., 1983 [rct],
1988 [rct]), multisystemic therapy (
Henggeler et al., 1991 [rct],
2002 [rct]), family systems therapy (
Joanning et al., 1992 [rct]), and multidimensional family therapy (
Dennis et al., 2002 [rct];
Liddle et al., 2001 [rct]). An integrated behavioral and family therapy model that combines a family systems model and CBT also appears efficacious (
Waldron et al., 2001 [rct]).
Recommendation 8. Treatment programs and interventions should develop procedures to minimize treatment dropout and to maximize motivation, compliance, and treatment completion [CG]
Treatment completion is the treatment variable most consistently related to positive outcome (
Alford et al., 1991;
Hser et al., 2001;
Williams and Chang, 2000). Related variables are motivation and compliance, which are also related to better outcomes (
Cady et al., 1996). Adolescent perceptions can also contribute to whether the youth will be engaged in treatment; this suggests that specialized, adolescent-focused engagement interventions are necessary.
Modifications of motivational interviewing or enhancement techniques for adolescents have shown promise for both evaluation and treatment based on limited treatment studies (
Colby et al., 1998 [rct];
Monti et al., 1999 [rct], 2001). This nonjudgmental, nondirective strategy is designed to move the adolescent to a “stage of change” in which the youth is more receptive to treatment or behavior change. Motivational interviewing and other brief interventions may serve to heighten motivation, increase self-efficacy, and provide personalized feedback and education tailored to specific substances and comorbid problems such as psychiatric disorders.
Recommendation 9. Medication can be used when indicated for the management of craving and withdrawal and for aversion therapy [OP]
Medications used to target alcohol-related cravings (e.g., naltrexone, acamprosate, ondansetron) are increasingly used among adults and have been effective in case reports in adolescents (
Solhkhah and Wilens, 1998). Their efficacy in adolescents has yet to be tested in controlled trials. These and aversive agents such as disulfiram could be considered for use in treatment-resistant adolescents.
Similarly, the use of medications to treat alcohol, benzodiazepine, or opiate withdrawal using medications, such as benzodiazepines (alcohol) and clonidine and buprenorphine (opiates), is not based on empirical research in adolescents but rather on research and experience with adults. Clinicians should use caution in considering pharmacological treatment for adolescents with comorbid SUDs and psychiatric disorders. The presence of SUDs or substance use may increase the potential for intentional or unintentional overdose with some psychotropic medications, especially in combination with some substances of abuse.
Recommendation 10. Treatment should encourage and develop peer support, especially regarding the nonuse of substances [CG]
A controversial element of traditional treatment programs is the widespread use of group treatment. There is substantial evidence that group treatment can have significant negative effects on outcomes (
Dishion et al., 2001). Emerging data suggest that this iatrogenic effect may be limited to more deviant, conduct-disordered youths who nevertheless make up a substantial portion of the adolescent SUD treatment population. Other studies show positive effects for group modalities (
Dennis et al., 2002 [rct];
Kaminer and Burleson, 1999 [rct];
Waldron et al., 2001 [rct]). Clinicians should take caution when forming groups for treatment and should consider alternative family-based or other modalities for more deviant youths.
Recommendation 11. Twelve-step approaches may be used as a basis for treatment. Attendance at Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) groups is an adjunct to professional treatment of SUDs and should be encouraged [CG]
Twelve-step approaches, using AA and NA as a basis for treatment, are perhaps the most common approaches for treatment and treatment programs in the United States. Attendance in aftercare treatment or self-support groups (e.g., AA or NA) is related to positive outcomes in several studies of adolescent SUD treatment (
Alford et al., 1991;
Williams and Chang, 2000;
Winters et al., 2000). Several other studies have found that attendance at self-support or aftercare groups is associated with higher rates of abstinence and other measures of improved outcome, when compared with those not participating in such groups after treatment (
Brown et al., 1994).
Twelve-step programs can be defined as having adolescents work on specific steps toward recovery, attendance at self-support groups (AA or NA), and obtaining the assistance of a sponsor who is another person in recovery from substance use problems. Developmentally appropriate, specific 12-step programs and self-support groups offer several benefits including a recovering (i.e., nonsubstance-using) peer group, available sponsors, and other types of support (
Jaffe, 1990,
2001). Although 12-step programs may be effective for many adolescents, they have not been subject to controlled clinical trials.
Recommendation 12. Programs/interventions should attempt to provide comprehensive services in other domains (e.g., vocational, recreational, medical, family, and legal) [CG]
Programs with more comprehensive services such as vocational counseling, recreational activities, and medical services (including birth control) have better outcomes than programs without those services (
Hser et al., 1999;
Williams and Chang, 2000). Per the success of multisystemic therapy, programs that deal with the social ecology or total life circumstances of the adolescent are likely to produce more lasting benefits than those that do not.
SCIENTIFIC DATA AND CLINCIAL CONSENSUS
Practice parameters are strategies for patient management, developed to assist clinicians in psychiatric decision making. American Academy of Child and Adolescent Psychiatry practice parameters, based on evaluation of the scientific literature and relevant clinical consensus, describe generally accepted approaches to assess and treat specific disorders or to perform specific medical procedures. These parameters are not intended to define the standard of care, nor should they be deemed inclusive of all proper methods of care or exclusive of other methods of care directed at obtaining the desired results. The clinician, after considering all the circumstances presented by the patient and his or her family, the diagnostic and treatment options available, and available resources, must make the ultimate judgment regarding the care of a particular patient.
This parameter was developed by Oscar G. Bukstein, M.D., and the Work Group on Quality Issues: William Bernet, M.D., and Oscar G. Bukstein, M.D., Co-Chairs, and Valerie Arnold, M.D., Joseph Beitchman, M.D., Jon Shaw, M.D., R. Scott Benson, M.D., Joan Kinlan, M.D., John McClellen, M.D., and Saundra Stock, M.D. AACAP staff: Kristin Kroeger Ptakowski.
A group of invited experts also reviewed the parameter. The Work Group on Quality Issues thanks William Arroyo, M.D., Judith Cohen, M.D., Michael A. Dawes, M.D., Deborah Deas, M.D., Mark Godley, Ph.D., Susan Godley, Ph.D., Scott Henggeler, Ph.D., Steven Jaffe, M.D., Yifrah Kaminer, M.D., Howard Liddle, Ph.D., Robert Milan, M.D., Paula D. Riggs, M.D., Cynthia Rowe, Ph.D., Deborah Simkin, M.D., Jose Szapocznik, Ph.D., and Naimah Weinberg, M.D.
This parameter was reviewed at the member forum at the 2002 annual meeting of the American Academy of Child and Adolescent Psychiatry.
During January to April 2004, a consensus group reviewed and finalized the content of this practice parameter. The consensus group consisted of representatives of relevant AACAP components as well as independent experts: William Bernet, M.D., Chair; Oscar G. Bukstein, M.D., author of the parameter; Saundra Stock, M.D., and Joseph Beitchman, M.D., representatives of the Work Group on Quality Issues; Thomas F. Anders, M.D., representative of the AACAP Council; Steven L. Jaffe, M.D., and Shashi Bhatia, M.D., representatives of the AACAP Assembly of Regional Organizations; Ramon Solhkhah, M.D., chair of the AACAP Committee on Substance Abuse and Addiction; Deborah R. Simkin, M.D., former chair of the AACAP Committee on Substance Abuse and Addictions; and Kristin Kroeger Ptakowski, Director of Clinical Affairs, AACAP.
This practice parameter was approved by AACAP Council in June 2004. This practice parameter is available on the Internet (www.aacap.org).